Abstract

To characterize the mutational patterns of acute lymphoblastic leukemia (ALL) we performed deep next generation sequencing of 872 cancer genes in 172 diagnostic and 24 relapse samples from 172 pediatric ALL patients. We found an overall greater mutational burden and more driver mutations in T-cell ALL (T-ALL) patients compared to B-cell precursor ALL (BCP-ALL) patients. In addition, the majority of the mutations in T-ALL had occurred in the original leukemic clone, while most of the mutations in BCP-ALL were subclonal. BCP-ALL patients carrying any of the recurrent translocations ETV6-RUNX1, BCR-ABL or TCF3-PBX1 harbored few mutations in driver genes compared to other BCP-ALL patients. Specifically in BCP-ALL, we identified ATRX as a novel putative driver gene and uncovered an association between somatic mutations in the Notch signaling pathway at ALL diagnosis and increased risk of relapse. Furthermore, we identified EP300, ARID1A and SH2B3 as relapse-associated genes. The genes highlighted in our study were frequently involved in epigenetic regulation, associated with germline susceptibility to ALL, and present in minor subclones at diagnosis that became dominant at relapse. We observed a high degree of clonal heterogeneity and evolution between diagnosis and relapse in both BCP-ALL and T-ALL, which could have implications for the treatment efficiency.

Highlights

  • Acute lymphoblastic leukemia (ALL), the most common pediatric cancer, is a genetically heterogeneous disease that arises from the malignant transformation of lymphoid progenitors at different developmental stages

  • We found an overall greater mutational burden and more driver mutations in T-cell acute lymphoblastic leukemia (ALL) (T-ALL) patients compared to B-cell precursor ALL (BCP-ALL) patients

  • We describe somatic mutations detected by deep targeted sequencing in a large cohort of pediatric ALL patients comprising different genetic subtypes

Read more

Summary

Introduction

Acute lymphoblastic leukemia (ALL), the most common pediatric cancer, is a genetically heterogeneous disease that arises from the malignant transformation of lymphoid progenitors at different developmental stages. Impressive improvements in treatment strategies during recent decades have resulted in survival rates exceeding 85%, relapsed ALL remains a leading cause of cancer-related death in children [1]. Recurrent large-scale chromosomal aberrations in B-cell precursor ALL (BCPALL) define genetic subtypes, which are used to support therapeutic decisions and correlate with the clinical outcome. Hyperdiploidy (51–67 chromosomes) and the t(12;21)ETV6-RUNX1 rearrangement are characteristic for the most common subtypes and are associated with a favorable outcome while MLL rearrangements and hypodiploidy have poor prognosis [2]. About 30% of the pediatric BCP-ALL patients remain uncharacterized by currently used genetic analyses at ALL diagnosis. The T-cell immunophenotype (T-ALL) comprises about 15% of pediatric ALL patients [3]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call